Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests. For many people, covid is an illness that blusters in and out of our lives as cases ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...